Diligence memo · auto-generated · as of July 2, 2026

ReWalk Robotics Ltd.

ReWalk Robotics Ltd. looks under-valued against its niche peers and is quiet on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

ReWalk Robotics Ltd. operates in Biotechnology, based in MARLBOROUGH.

Sub-sector tags: robotics.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

ReWalk Robotics Ltd. has raised $94M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $40M on 2021-02-19.

Most recent recorded round closed around 2025-01-07.

Valuation (modeled)modeled

Provath models ReWalk Robotics Ltd. at approximately $37M (range $15M–$52M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.19× the median modeled value of Series C Biotechnology companies in 2025–2027 (58 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 9 months.

Last raise 18 mo ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

The last round was 3.3× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 90% of Biotechnology peers (4293 compared).

Modeled value ranks above 39% of those peers.

Closest niche peers: Newleos Therapeutics, Inc., Biolinq Inc, Atsena Therapeutics, Inc., Galvanize Therapeutics, Inc., X4 Pharmaceuticals, Inc.

Peoplefiled

23 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.